Lillian Veatch
Primary Care · Albemarle, NCNPI 1801427331
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 336 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,983 and has fallen 97.7% since, to $46 in 2025. Among primary care clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$620
- AbbVie$495
- Amgen$482
- Astellas Pharma US Inc$446
- AstraZeneca$406
- Lilly USA, LLC$394
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,59297%
- Education$1953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $620 |
| AbbVie | 36 | $495 |
| Amgen | 23 | $482 |
| Astellas Pharma US Inc | 17 | $446 |
| AstraZeneca | 25 | $406 |
| Lilly USA, LLC | 23 | $394 |
| Boehringer Ingelheim | 19 | $351 |
| Exact Sciences | 12 | $299 |
| Xeris Pharmaceuticals, Inc. | 11 | $233 |
| Novartis | 9 | $150 |
| Pfizer | 9 | $148 |
| Sanofi-aventis U.S. LLC | 7 | $148 |
| Sumitomo Pharma America, Inc. | 6 | $146 |
| Bayer | 8 | $143 |
| GSK | 8 | $140 |
| Kowa Pharmaceuticals America, Inc. | 7 | $119 |
| Idorsia Pharmaceuticals US Inc | 6 | $115 |
| Medtronic | 5 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $110 |
| Mylan Specialty L.p. | 5 | $95 |
| Esperion Therapeutics, Inc. | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $77 |
| Phathom Pharmaceuticals, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Shield Therapeutics Inc | 4 | $61 |
| Currax Pharmaceuticals LLC | 3 | $53 |
| Bausch Health US, LLC | 3 | $49 |
| Merck | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Intuity Medical Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$120
- Cologuard Collection Kit$112
How this compares
$5,787 in reported general payments places this provider in the 95th percentile of 236 primary care providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $117,765 |
| MounjaroTirzepatide | 80 | $92,564 |
| EliquisApixaban | 85 | $68,186 |
| JardianceEmpagliflozin | 51 | $59,659 |
| TrulicityDulaglutide | 12 | $16,708 |
| MyrbetriqMirabegron | 24 | $15,079 |
| FarxigaDapagliflozin Propanediol | 16 | $14,634 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $10,308 |
| LinzessLinaclotide | 12 | $8,175 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,547 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,635 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 24 | $4,661 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,825 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 162 | $3,662 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog Mix 70-30 | $620 | $120,43099 claims |
| Lilly USA, LLCMounjaro, Trulicity | $394 | $109,27292 claims |
| PfizerEliquis | $148 | $68,18685 claims |
| Boehringer IngelheimJardiance | $351 | $59,65951 claims |
| Astellas Pharma US IncMyrbetriq | $446 | $15,07924 claims |
| AstraZenecaFarxiga | $406 | $14,63416 claims |
| GSKAnoro Ellipta, Shingrix | $140 | $9,51427 claims |
| AbbVieLinzess | $495 | $8,17512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 236 primary care providers in North Carolina.
Other primary care in Albemarle
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
- Crystal GoinsFayetteville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.